GIP and obesity due to melanocortin 4 receptor deficiency: Two phase 3 trials have addressed the potential positive effect of the dual GIP and GLP-1 receptor agonist (tirzepatide) for obesity (SURMOUNT-1, patients with obesity only, and SURMOUNT-2, for patients with obesity and type 2 diabetes).